Short Summary
Samsung and co‑petitioners have filed an IPR petition seeking to invalidate 18 claims of Omni MedSci’s wearable health‑monitoring patent. They argue the claims are obvious over a combination of prior‑art references and that collateral estoppel bars re‑litigation.
Detailed Summary
In Petition IPR2025-01251, Samsung Electronics and its affiliates challenge U.S. Patent No. 10,874,304, which claims a wearable physiological measurement system that integrates a multi‑LED light source, signal‑to‑noise enhancement, and wireless communication with a smart device and cloud. The petition asserts that the claims are unpatentable under 35 U.S.C. §103, relying on a series of prior‑art references—Lisogurski, LeBoeuf, Tran, Carlson, and Marbach—to show obviousness, and invokes collateral estoppel based on earlier IPRs (IPR2019‑00916 and IPR2021‑00453) that found identical limitations unpatentable. The petition also contends that the Board’s discretionary denial provisions (§ 325(d) and § 314(a)) are inapplicable, seeking institution of the trial.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before local courts. Understanding the court's reasoning in SAMSUNG ELECTRONICS CO., LTD. et al. vs OMNI MEDSCI, INC. is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
Google LLCvsSecure Communication Technologies, LLC
Google petitions the PTAB to invalidate Secure Communication Technologies' ’736 patent, asserting that the claims are anticipated or obvious over the Eagle and Mgrdechian references. The petition argues the prior art was never considered during prosecution and requests institution of the IPR.
Liberty Mutual Insurance Company et al.vsIntellectual Ventures I
Liberty Mutual and Comerica have filed an IPR petition seeking cancellation of all 37 claims of Intellectual Ventures' 722 patent on the ground of obviousness over prior‑art event‑notification systems. The petition relies on expert testimony and argues that discretionary denial is unwarranted.
Sportradar AG et al.vsSportsCastr Inc. (d/b/a PANDA Interactive)
Sportradar has filed an IPR petition challenging SportsCastr’s ‘697 patent covering low‑latency sports video and data streaming. The petition alleges obviousness over five prior‑art references and seeks institution of the review.
Berkshire Hathaway Energy Company et al.vsMES, Inc.
Petitioners and Birchtech Corp. jointly moved to have their settlement agreements treated as business confidential information under 35 U.S.C. §317(b) and related Board rules.
Biofrontera Incorporated et al.vsSun Pharmaceutical Industries, Inc.
Biofrontera has filed a rehearing request challenging the Board’s denial to institute an IPR on Sun Pharmaceutical’s photodynamic therapy patent, arguing the claims are highly vulnerable and that institution would prevent inconsistent rulings.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.